99% purity peptide in vials, white lyophilized powder, pre-order available
4 Inquiries
141758-74-9
Research Grade
99%
qingdao
5mg;10mg;15mg;20mg;30mg;40mg;50mg;100mg;500mg
2026-12-04
Cosmetics
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceExendin-4 is a 39 amino acid polypeptide and incretin mimetic involved in the glucose-dependent enhancement of insulin secretion. It was first isolated from Gila monster saliva. It also promotes the reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain. The synthetic form, Exenatide, is a glucagon-like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II, has a long half-life.
Exenatide is the first drug in a new class of anti-diabetics known as the incretin mimetics, and it is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes who are taking metformin, a sulfonylurea, or both, but have not achieved adequate glycemic control. Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). GLP-1 is naturally released from cells in the GI tract in response to food intake and acts on its receptor on b-cells to potentiate glucose-stimulated insulin secretion. Exenatide is a long-acting agonist at the GLP-1 receptor. It is a synthetic version of a 39-amino acid peptide found in the salivary secretions of the Gila monster lizard.also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia.
ChEBI: A bioactive polypeptide of 39 amino acid residues isolated from the saliva of the Gila monster (Heloderma suspectum). High-affinity glucagon-like peptide 1 (GLP-1) receptor agonist (Kd = 136 pM); potently indu es cAMP formation without stimulating amylase release in pancreatic acini; potentiates glucose-induced insulin secretion in isolated rat islets; protects against glutamate-induced neurotoxicity. A synthetic version is called exenatide.
Exendin-4 is an incretin mimetic peptide, which is composed of 39 amino acids. It is an analog of glucagon-like peptide 1 (GLP-1), and an insulinotropic agent, with a long half-life. Exendin-4 was historically isolated from the venom of Gila monster lizard calledHeloderma suspectum.
Exendin-4 Recombinant produced in E.Coli is a non-glycosylated polypeptide chain containing 39 amino acids and having a molecular mass of approximately 4.2kDa. Exendin-4 is purified by proprietary chromatographic techniques.Basic Info-
Product Name:
Exendin-4
Other Name:HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2;Exenatide (Exendin-4);Exenatide free base;XENDIN-4;EXENDIN-4;M.W. 4186.61 C184H282N50O60S;HIS-GLY-GLU-GLY-THR-PHE-THR-SER-ASP-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-ILE-GLU-TRP-LEU-LYS-ASN-GLY-GLY-PRO-SER-SER-GLY-ALA-PRO-PRO-PRO-SER-NH2;HIS-GLY-GLU-GLY-THR-PHE-THR-SER-ASP-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-ILE-GLU-TRP-LEU-LYS-ASN-GLY-GLY-PRO-SER-SER-GLY-ALA-PRO-PRO-PRO-SER-NH2: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
CAS No.:141758-74-9
Molecular Formula:C184H282N50O60S
InChIKeys:HTQBXNHDCUEHJF-XWLPCZSASA-N
Molecular Weight:4187
EC Number:686-356-3
Color/Form:White to off-white powder
HScode:2933290000
Categories:
Characteristics-
XLogP3:
-21
Water Solubility:Soluble in water (1 mg/ml)
Storage Conditions:Bydureon should be stored in the refrigerator at 36 °F to 46 °F (2 °C to 8 °C), up to the expiration date or until preparing for use. Bydureon should not be used past the expiration date. The expiration date can be found on the carton, on the cover of the single-dose tray, or on the pen label. Do not freeze Bydureon. Do not use Bydureon if it has been frozen. Protect from light. Bydureon single-dose tray can be kept at room temperature not to exceed 77 °F (25 °C).; Prior to first use, Byetta must be stored refrigerated at 36 °F to 46 °F (2 °C to 8 °C). After first use, Byetta can be kept at a temperature not to exceed 77 °F (25 °C). Do not freeze. Do not use Byetta if it has been frozen. Byetta should be protected from light.
Toxicity:IDENTIFICATION AND USE: Exenatide is a white to off-white powder formulated into solution for subcutaneous use. Exenatide is available in both a twice daily formulation and an extended-release formulation that is administered weekly. Exenatide is a synthetic, long-acting human glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetic). It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. HUMAN EXPOSURE AND TOXICITY: Overdose of exenatide has been reported in a clinical study. Effects have included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations. Post marketing reports also include acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis requiring hospitalization and serious hypersensitivity reactions (e.g. anaphylaxis and angioedema). Deterioration of renal function (e.g., increased serum creatinine concentrations, renal impairment/insufficiency, and chronic renal failure, acute renal failure sometimes requiring hemodialysis or kidney transplantation) has also been reported with the use of exenatide. Exenatide extended-release also caused thyroid C-cell tumors at clinically relevant exposures in rats. It is unknown whether the drug causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. Therefore, exenatide extended release is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2. ANIMAL STUDIES: Exenatide had no adverse effects on fertility when given to male mice at doses up to 760 ug/kg/day. However, exenatide did cause developmental toxicity in rats, mice and rabbits. Fetuses from pregnant rats given subcutaneous doses of exenatide extended-release at 0.3, 1, or 3 mg/kg on gestation days 6, 9, 12, and 15 demonstrated reduced fetal growth at all doses and produced skeletal ossification deficits at 1 and 3 mg/kg in association with maternal effects (decreased food intake and decreased body weight gain). In pregnant mice given sc doses of 6, 68, 460, or 760 ug/kg/day from gestation day 6 through 15 (organogenesis), cleft palate (some with holes) and irregular fetal skeletal ossification of rib and skull bones were observed at 6 ug/kg/day. In pregnant rabbits given sc doses of 0.2, 2, 22, 156, or 260 ug/kg/day from gestation day 6 through 18 (organogenesis), irregular fetal skeletal ossifications were observed at 2 ug/kg/day. Studies for the carcinogenicity potential of exenatide were also conducted in rats. Benign thyroid C-adenomas were observed in female rats given extenatide by sc injection at doses of 18, 70, or 250 ug/kg/day. In another carcinogenicity study with exenatide extended-release male and female rats were administrated doses of 0.3, 1.0, and 3.0 mg/kg by subcutaneous injection every other week.
Critical Temperature & Pressure:−20°C
Research-
Class:
GLP-1 receptor agonist (exendin-based, 39-amino-acid peptide)
Status:FDA-approved (Byetta 2005, Bydureon 2012)
Mechanism:A synthetic 39-amino-acid peptide (exendin-4) that acts as a GLP-1 receptor agonist. It is not a GLP-1 analog but shares 53% sequence homology with human GLP-1. Exenatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces food intake. Bydureon is the extended-release formulation.
EC50 (GLP1R Ic50):3.22 nM
Source:Exendin-4 binding data: Eng J, et al. J Biol Chem. 1992;267(11):7402-7405. DrugBank: DB01276.DOI
Clinical Development:FDA:Byetta, Bydureon BCise (approved 2005-04-28)
References-
ChEMBL:
CHEMBL486
DrugBank:KEGG DRUG:PubChem:Literature:Disclaimer:Exenatide is FDA-approved as a prescription medicine (Byetta, Bydureon) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
Carcinogenicity, Category 2
Reproductive toxicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Warning
Hazard statement(s) H351 Suspected of causing cancer
H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Cosmetics
-
Location:
Room 204, Unit 1, Building 3, Liming 1st District, Choujiang Subdistrict, Wenwu City, Jinhua City, China (Zhejiang) Pilot Free Trade Zone
-
Year of Establishment:
2026
-
-
Inquiry History4 Inquiries
Country Product Purchase Quantity Date Posted
Philippines
Exenatide (CAS: 141758-74-9)
10 G Sep 19, 2026
Philippines
Exenatide
10 G Sep 16, 2026
Philippines
Exenatide
10 G Aug 13, 2026
United States
Exenatide
5 Mar 11, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Source Supplier Vial Lyophilized Peptide Raw Material, Continuous New Item Release For Rich Categories
Research Grade / 99%
$115/UNIT EXW
-
-
-
-
Chinese Supplier Lyophilized Peptide Raw Powder, Unified Factory Release Standard With Consistent Quality
Research Grade / 99%
$155/UNIT EXW
-
-
-
-
High Quality Vial Lyophilized Peptide Powder, Sufficient Factory Capacity, Schedule Available For Large Bulk
Research Grade / 99%
$80/UNIT EXW
-
-
-
-
Premium Grade Lyophilized Peptide Raw Powder, Warehouse Direct Delivery Without Multi-level Middleman
Research Grade / 99%
$110/UNIT EXW
-
-
-
-
High Quality Lyophilized Peptide Raw Powder, Large-scale Domestic Factory With Stable Order Fulfillment
Research Grade / 99%
$100/UNIT EXW
-
-
-
-
Peptide raw powder in vials, 99% purity white lyophilized
Research Grade / 99%
$60/UNIT EXW
-